Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 29.30 -1.13 (3.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.43 | 52 Week High | $18.62 | |||
| Open | $30.07 | 52 Week Low | $2.85 | |||
| Day High | $30.10 | P/E | N/A | |||
| Day Low | $28.63 | EPS | $-1.02 | |||
| Volume | 3,950,475 | |||||
